{"id":25900,"date":"2024-08-06T11:57:48","date_gmt":"2024-08-06T09:57:48","guid":{"rendered":"https:\/\/ggba.swiss\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/"},"modified":"2024-08-06T12:00:30","modified_gmt":"2024-08-06T10:00:30","slug":"ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/","title":{"rendered":"AC Immune re\u00e7oit la d\u00e9signation Fast Track de la FDA pour son traitement de la maladie d&rsquo;Alzheimer"},"content":{"rendered":"\n<p>Bas\u00e9e \u00e0 Lausanne, <a href=\"https:\/\/www.acimmune.com\/\">AC Immune<\/a> est une soci\u00e9t\u00e9 biopharmaceutique au stade clinique sp\u00e9cialis\u00e9e dans la m\u00e9decine de pr\u00e9cision pour les maladies neurod\u00e9g\u00e9n\u00e9ratives. Les technologies de la soci\u00e9t\u00e9, SupraAntigen\u00ae et Morphomer\u00ae, soutiennent un pipeline diversifi\u00e9 de candidats th\u00e9rapeutiques de premier et de meilleur niveau.<\/p>\n\n\n\n<p>Le m\u00e9dicament exp\u00e9rimental JNJ-2056, d\u00e9riv\u00e9 de la plateforme SupraAntigen\u00ae d&rsquo;AC Immune, vise \u00e0 g\u00e9n\u00e9rer des anticorps protecteurs \u00e0 large spectre contre la prot\u00e9ine Tau pathologique. Cette approche pourrait r\u00e9duire l&rsquo;agr\u00e9gation de la prot\u00e9ine Tau et ralentir la progression de la maladie chez les patients atteints de la maladie d&rsquo;Alzheimer. Dans les \u00e9tudes cliniques, le JNJ-2056 s&rsquo;est r\u00e9v\u00e9l\u00e9 prometteur en induisant une forte r\u00e9ponse anticorps contre les formes pathologiques de la prot\u00e9ine Tau.<\/p>\n\n\n\n<p>La d\u00e9signation Fast Track de la FDA reconna\u00eet le potentiel de la th\u00e9rapie d&rsquo;AC Immune \u00e0 apporter des b\u00e9n\u00e9fices significatifs aux patients. Andrea Pfeifer, CEO d&rsquo;AC Immune SA, a d\u00e9clar\u00e9 : \u00ab La d\u00e9signation Fast Track est une reconnaissance importante de la diff\u00e9renciation et de la valeur potentielle de notre immunoth\u00e9rapie active anti-pTau, ACI-35.030, pour les patients. L&rsquo;\u00e9tude de phase 2b ReTain est la premi\u00e8re \u00e0 tester une immunoth\u00e9rapie active dans une population pr\u00e9clinique atteinte de la maladie d&rsquo;Alzheimer. Nous pensons que cette modalit\u00e9 a le potentiel d&rsquo;offrir des avantages th\u00e9rapeutiques, ainsi que des avantages en termes de commodit\u00e9 et d&rsquo;acc\u00e8s.&nbsp;\u00bb<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Des solutions innovantes pour la maladie d&rsquo;Alzheimer et les troubles neurod\u00e9g\u00e9n\u00e9ratifs<\/h4>\n\n\n\n<p>Le d\u00e9veloppement de JNJ-2056 est men\u00e9 dans le cadre d&rsquo;un accord de licence mondial avec Janssen Pharmaceuticals, Inc. Janssen finance et conduit enti\u00e8rement l&rsquo;essai de phase 2b ReTain, qui recrute actuellement des participants atteints de la maladie d&rsquo;Alzheimer au stade pr\u00e9clinique et n&rsquo;ayant pas encore pr\u00e9sent\u00e9 de sympt\u00f4mes cliniques.<\/p>\n\n\n\n<p>Cette nouvelle \u00e9tape s&rsquo;appuie sur les r\u00e9alisations ant\u00e9rieures d&rsquo;AC Immune, notamment <a href=\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/\">un partenariat important avec Takeda pour l&rsquo;immunoth\u00e9rapie ACI-24.060<\/a>. Gr\u00e2ce \u00e0 l&rsquo;avancement continu de son portefeuille th\u00e9rapeutique, AC Immune reste \u00e0 la pointe des solutions innovantes pour la maladie d&rsquo;Alzheimer et d&rsquo;autres troubles neurod\u00e9g\u00e9n\u00e9ratifs. Les efforts de l&rsquo;entreprise visent \u00e0 donner un nouvel espoir \u00e0 des millions de patients et \u00e0 leurs familles \u00e0 travers le monde.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L&rsquo;ACI-35.030 d&rsquo;AC Immune (d\u00e9sormais appel\u00e9 JNJ-2056), un candidat \u00e0 l&rsquo;immunoth\u00e9rapie active ciblant la forme pathologique de la prot\u00e9ine Tau, a re\u00e7u la d\u00e9signation Fast Track de la Food and Drug Administration (FDA) des \u00c9tats-Unis.<\/p>\n","protected":false},"author":6,"featured_media":25897,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1188,1141,1171,1142],"class_list":["post-25900","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-healthcare-fr-2","tag-personalized-medicine-fr-2","tag-pharma-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AC Immune receives FDA Fast Track for Alzheimer\u2019s therapy<\/title>\n<meta name=\"description\" content=\"Le candidat \u00e0 l&#039;immunoth\u00e9rapie active ciblant la forme pathologique de la prot\u00e9ine Tau d&#039;AC Immune a re\u00e7u la d\u00e9signation Fast Track de la FDA.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune receives FDA Fast Track for Alzheimer\u2019s therapy\" \/>\n<meta property=\"og:description\" content=\"Le candidat \u00e0 l&#039;immunoth\u00e9rapie active ciblant la forme pathologique de la prot\u00e9ine Tau d&#039;AC Immune a re\u00e7u la d\u00e9signation Fast Track de la FDA.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-06T09:57:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-06T10:00:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"AC Immune re\u00e7oit la d\u00e9signation Fast Track de la FDA pour son traitement de la maladie d&rsquo;Alzheimer\",\"datePublished\":\"2024-08-06T09:57:48+00:00\",\"dateModified\":\"2024-08-06T10:00:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/\"},\"wordCount\":427,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg\",\"keywords\":[\"Healthcare\",\"Personalized Medicine\",\"Pharma\",\"R&amp;D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/\",\"name\":\"AC Immune receives FDA Fast Track for Alzheimer\u2019s therapy\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg\",\"datePublished\":\"2024-08-06T09:57:48+00:00\",\"dateModified\":\"2024-08-06T10:00:30+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Le candidat \u00e0 l'immunoth\u00e9rapie active ciblant la forme pathologique de la prot\u00e9ine Tau d'AC Immune a re\u00e7u la d\u00e9signation Fast Track de la FDA.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"AC Immune est une soci\u00e9t\u00e9 biopharmaceutique de phase clinique qui a pour objectif de devenir un leader mondial de la m\u00e9decine de pr\u00e9cision pour les maladies neurod\u00e9g\u00e9n\u00e9ratives. | \u00a9 AC Immune\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune re\u00e7oit la d\u00e9signation Fast Track de la FDA pour son traitement de la maladie d&#8217;Alzheimer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AC Immune receives FDA Fast Track for Alzheimer\u2019s therapy","description":"Le candidat \u00e0 l'immunoth\u00e9rapie active ciblant la forme pathologique de la prot\u00e9ine Tau d'AC Immune a re\u00e7u la d\u00e9signation Fast Track de la FDA.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/","og_locale":"fr_FR","og_type":"article","og_title":"AC Immune receives FDA Fast Track for Alzheimer\u2019s therapy","og_description":"Le candidat \u00e0 l'immunoth\u00e9rapie active ciblant la forme pathologique de la prot\u00e9ine Tau d'AC Immune a re\u00e7u la d\u00e9signation Fast Track de la FDA.","og_url":"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-08-06T09:57:48+00:00","article_modified_time":"2024-08-06T10:00:30+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"AC Immune re\u00e7oit la d\u00e9signation Fast Track de la FDA pour son traitement de la maladie d&rsquo;Alzheimer","datePublished":"2024-08-06T09:57:48+00:00","dateModified":"2024-08-06T10:00:30+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/"},"wordCount":427,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg","keywords":["Healthcare","Personalized Medicine","Pharma","R&amp;D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/","url":"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/","name":"AC Immune receives FDA Fast Track for Alzheimer\u2019s therapy","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg","datePublished":"2024-08-06T09:57:48+00:00","dateModified":"2024-08-06T10:00:30+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Le candidat \u00e0 l'immunoth\u00e9rapie active ciblant la forme pathologique de la prot\u00e9ine Tau d'AC Immune a re\u00e7u la d\u00e9signation Fast Track de la FDA.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg","width":1180,"height":811,"caption":"AC Immune est une soci\u00e9t\u00e9 biopharmaceutique de phase clinique qui a pour objectif de devenir un leader mondial de la m\u00e9decine de pr\u00e9cision pour les maladies neurod\u00e9g\u00e9n\u00e9ratives. | \u00a9 AC Immune"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/ac-immune-recoit-la-designation-fast-track-de-la-fda-pour-son-traitement-de-la-maladie-dalzheimer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"AC Immune re\u00e7oit la d\u00e9signation Fast Track de la FDA pour son traitement de la maladie d&#8217;Alzheimer"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/25900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=25900"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/25900\/revisions"}],"predecessor-version":[{"id":25902,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/25900\/revisions\/25902"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/25897"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=25900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=25900"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=25900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}